Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S.

Core Insights - Eli Lilly has launched a new program called "Employer Connect" aimed at increasing employer coverage for obesity drugs in the U.S., addressing a significant barrier to patient access [1][5] - The program allows employers to pay a net discounted price of $449 per month for a multi-dose form of Zepbound, providing clearer visibility on costs without involving rebates [6][10] - Approximately 20% of firms with over 200 employees currently cover GLP-1 drugs for weight loss, with 43% of larger firms (5,000+ employees) offering such coverage as of October [3][2] Employer Coverage and Program Details - The new platform offers flexibility for employers in designing benefits for obesity treatments, aiming to reduce out-of-pocket costs for employees while managing company expenses [5][7] - Employers can select from over a dozen third-party program administrators to tailor benefits according to their specific workforce needs, including functions like enrollment and claims management [7][8] - Lilly plans to expand the number of program administrators available on the platform, which currently includes various health service providers [9] Market Context and Future Outlook - The uneven coverage of obesity drugs by employers is highlighted, with Lilly noting that high costs prevent nearly half of commercially insured individuals from accessing treatment [2] - There is potential for more employers to opt into obesity coverage in the coming months, with some possibly waiting until 2027 to make decisions [4] - Government insurance beneficiaries may also gain easier access to obesity drugs due to recent agreements that allow Medicare to cover these medications for the first time later this year [10]